Globus Medical Inc. Class A (GMED)
NYSE: GMED · Surgical & Medical Instruments & Apparatus · Audubon, PA
Our rating: Positive
Positive reaffirmed at $71.05, moderate conviction, November 6, 2026.
Breaks if: The Positive view is invalidated if reported revenue growth falls below 6% in two consecutive quarterly prints over the next 12 months — the level at which post-merger base effects would have fully normalized and an underlying organic deceleration would be exposed. Separately, if trailing free-cash-flow margin drops below 14% within four quarters, the valuation anchor built on robust cash conversion no longer holds.
Key figures
| Market value | $9.0B |
|---|---|
| Revenue, last 12 months | $3.1B |
| Net income, last 12 months | $558M |
| Free cash flow, last 12 months | $767M |
| Price to earnings | 16.1× |
| Free cash flow yield | 8.5% |
| Dividend yield | 0.0% |
| Operating margin | 21.6% |
| Return on equity | 12.1% |
| Beta to the S&P 500 | 0.93 |
| Volatility, annualized | 43.0% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $764M | −0.7% | $1.04 | $225M |
| June 30, 2026 | $790M | 5.9% | $1.10 | $177M |
| March 31, 2026 | $760M | 27.0% | $0.90 | $163M |
| December 31, 2025 | $826M | 25.7% | $1.02 | $202M |
| September 30, 2025 | $769M | 22.9% | $0.88 | $214M |
| June 30, 2025 | $745M | 18.4% | $1.49 | $31M |
| March 31, 2025 | $598M | −1.4% | $0.54 | $141M |
| December 31, 2024 | $657M | 6.6% | $0.19 | $193M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.95B: Claude 22%, Gemini 25%, Mistral 8%
- Diluted earnings per share are at least $1.02: Claude 52%, Gemini 70%, Mistral 46%
- Free cash flow for the quarter is at least $0.20B: Claude 55%, Gemini 80%, Mistral 54%
12 ledger entries and 35 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.